News

Treatment with Simponi Aria (golimumab) for one year reduced the signs and symptoms of ankylosing spondylitis (AS) among adult patients with active disease, Phase 3 trial data show. The study, “Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE…

High levels of the protein chitotriosidase in the blood are associated with more disease activity in ankylosing spondylitis patients. This protein might be a useful prognostic marker. The study, “Serum chitotriosidase and neopterin levels in patients with ankylosing spondylitis,” was published in Therapeutic Advances in Musculoskeletal Disease. Chitotriosidase is…

Gender-based differences in fecal metabolites in ankylosing spondylitis patients may provide clues about differences regarding male versus female disease progression. The study with that finding, “GC-MS-based fecal metabolomics reveals gender-attributed fecal signatures in ankylosing spondylitis,” was published in Scientific Reports. There are a number of differences in how…

A high-fat diet and long-term exposure to air pollution are both associated with worse outcomes in patients with ankylosing spondylitis, a study shows. The study, “Effect of food intake and ambient air pollution exposure on ankylosing spondylitis disease activity,” was published in the journal Advances…

Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bathdissertation, she analyzed Brexit’s long-term impact…

Anti-TNF alpha therapy is able to significantly restore ankylosing spondylitis patients’ capacity to exercise after a treatment period of four months, a small study suggests. After treatment, patients in the study improved in objective measures of cardiorespiratory fitness, such as peak oxygen uptake during exercise, maximum work…

High levels of C-reactive protein, a marker of systemic inflammation, at the onset of back pain can help predict which patients go on to develop ankylosing spondylitis, a study shows. The study, “Baseline high-sensitivity C-reactive protein predicts the risk of incident ankylosing spondylitis: Results of a community-based prospective study,”…

Rare diseases affect about 30 million Americans — roughly the same number as those with type 2 diabetes. Yet only 5 percent of the estimated 7,000 rare diseases known to science have cures or treatments approved by the U.S. Food and Drug Administration (FDA). Raising awareness of those illnesses and highlighting…

Treatment with anti-TNF-alpha therapies can lead to improved lumbar spine curvature and better clinical outcomes in patients with ankylosing spondylitis, study shows. The study, “Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-α versus nonsteroidal anti-inflammatory drugs and sulfasalazine,” was published in the European Spine Journal.

Ankylosing spondylitis (AS) patients have a more than 50% increased risk of developing blood vessel clots, according to a population-based Canadian study. “Clinicians should have an increased awareness of this complication so that they can provide the best care possible to their patients,” Antonio Aviña-Zubieta, PhD, a senior scientist…